Synlogic, Inc., a Cambridge, Massachusetts-based biotechnology company focused on the development of therapeutic microbes, received a $5M investment from the Bill & Melinda Gates Foundation in the previously announced Series A funding round (read here).
Along with developing its technology platform and proprietary therapeutic applications, Synlogic will collaborate with the Gates Foundation on applications relevant to the developing world.
Founded in 2014 by Jim Collins Ph.D., co-founder, Synlogic leverages a proprietary microbial engineering platform for the development of therapeutic microbes and advance a preclinical pipeline across several clinical applications. Concurrent with the financing, the company added Paul Miller, Ph.D., as Chief Scientific Officer, and Alison Silva as Chief Operating Officer.
FinSMEs
07/10/2014